ICPT CODE: AMA CPT 0106U
TITLE: 13C-Spirulina Gastric Emptying Breath Test (GEBT)
TYPE OF CODE: CPT Proprietary Laboratory Analysis (PLA) Code
EFFECTIVE DATE: October 1, 2019
CODE DESCRIPTION: Gastric emptying evaluation; Serial collection of 7 timed breath specimens, utilizes Non-radioisotope carbon-13 (13C) Spirulina substrate, Analysis of each specimen by high precision gas isotope ratio mass spectrometry (GIRMS), Reported as rate of 13CO2 excretion (kPCD metric) at each measurement time.
INTENDED USE POPULATION: Patients age 18+ symptomatic for gastroparesis
COVERAGE DECISION DATES: July 29, 2020
CMS APPROVING BODY: Jurisdictions JJ, JM and MolDx, Palmetto GBA.
BASIS OF APPROVAL: FDA approval and “analytic and clinical validity as well as clinical utility in the evaluation of gastroparesis.”
REIMBURSMENT: $874.49 (national CMS fee schedule published January 1, 2021)
GEBT, the only FDA-approved breath test for measuring the rate of solid phase gastric emptying, has an exclusive CPT code for billing and is covered by Medicare.
CPT CODE: AMA CPT 0106U
TITLE: 13C-Spirulina Gastric Emptying Breath Test (GEBT)
TYPE OF CODE: CPT Proprietary Laboratory Analysis (PLA) Code
EFFECTIVE DATE: October 1, 2019
CODE DESCRIPTION: Gastric emptying evaluation; Serial collection of 7 timed breath specimens, utilizes Non-radioisotope carbon-13 (13C) Spirulina substrate, Analysis of each specimen by high precision gas isotope ratio mass spectrometry (GIRMS), Reported as rate of 13CO2 excretion (kPCD metric) at each measurement time.
Intended Use Population: Patients age 18+ symptomatic for gastroparesis
Coverage Decision Date: July 29, 2020
CMS Approving Body: Jurisdictions JJ, JM and MolDx, Palmetto GBA.
Basis of Approval:
FDA approval and “analytic and clinical validity as well as clinical utility in the evaluation of gastroparesis.”
Reimbursement: $874.49 (national CMS fee schedule published January 1, 2021)
